Larvol Delta - Societal-CDMO-Selected-By-AmyriAD-Pharma-to-Provide-Clinical-Trials-Services-to-Support-Pivotal-Phase-3-Program-For-Alzheimers-Disease-Treatment-AD101

AD101 - AmyriAD

https://www.globenewswire.com/news-release/2022/06/01/2454067/30326/en/Societal-CDMO-Selected-By-AmyriAD-Pharma-to-Provide-Clinical-Trials-Services-to-Support-Pivotal-Phase-3-Program-For-Alzheimer-s-Disease-Treatment-AD101.html

Jun 1, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev